Skip to content

Clinical study on the exploration of effective dosage,safety and comfort of Anricafen for moderate pain

Clinical study on the exploration of effective dosage,safety and comfort of Anricafen for moderate pain

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117028
Enrollment
Unknown
Registered
2026-01-19
Start date
2026-01-19
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia

Interventions

Phase One:For Anrikefon, the sequential method is used for drug administration, with the dosage for the next subject adjusted based on the analgesic response of the previous subject.

Sponsors

the Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, no gender restriction (the ratio of male to female in the first stage is 1:1); 2. BMI 18-27 kg/m²; 3. Acute moderate pain: 24 hours after abdominal surgery, NRS score is >=4 and <=6 (measured within 30 minutes before administration); 4. No analgesic drugs were used within 48 hours before operation; 5. Voluntarily sign the informed consent form and understand and complete the NRS score; 6. Additional requirements for the second phase: Participants must not have participated in the first phase of this study.

Exclusion criteria

Exclusion criteria: 1. Allergy to opioids (especially ? agonists) or morphine; 2. History of central nervous system disease (epilepsy, depression, cognitive impairment); 3. Severe cardiovascular disease (myocardial infarction, heart failure in the past 3 months) or history of hypotension (basal systolic blood pressure <90 mmHg); 4. Severe renal insufficiency; 5. Participated in other clinical trials or had a history of drug abuse (alcoholism, drug abuse) in the past 1 month; 6. Pregnant women, nursing and other special groups; 7. Other circumstances deemed unsuitable for enrollment by the investigator (e.g., severe infections, malignancies).

Design outcomes

Primary

MeasureTime frame
Safety and comfort;ED??/ED??;

Secondary

MeasureTime frame
Rapid-Onset Analgesia Score;

Countries

China

Contacts

Public ContactLi Jinlu

the Second Affiliated Hospital of Soochow University

lijinlu888@163.com+86 512 6778 3879

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026